Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Ambrose

Showing results (171-180 of 250) with videos related to

Pageof 25
Sort By:
Journal of Orthopaedic Trauma|October 21, 2024
Effects of Tranexamic Acid on Human Osteoblasts as Proxy for Fracture HealingAlexander Abraham, D Nicole Meyers, William D Rieger, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2013
E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironmentTao Yang, Ingo Grafe, Yangjin Bae, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2011
Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh modelSharath S Hegde, Olanrewaju O Okusanya, Robert Skinner, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2002
Fluid flow increases mineralized matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a dose-dependent mannerGregory N Bancroft, Vassilios I Sikavitsas, Juliette van den Dolder, et al.
Diagnostic Microbiology and Infectious Disease|April 26, 2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selectionOlanrewaju O Okusanya, Brian T Tsuji, Jurgen B Bülitta, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2011
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineSujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, et al.
Journal of Clinical Pharmacology|August 3, 2013
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumoniaScott A Van Wart, Alan Forrest, Tatiana Khariton, et al.
Diagnostic Microbiology and Infectious Disease|January 20, 2009
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococciPaul G Ambrose, Alison K Meagher, Julie A Passarell, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase InhibitorPaul G Ambrose, Brian D VanScoy, Michael Trang, et al.
Pageof 25

Showing results (171-180 of 250) with videos related to

Sort By:
Pageof 25
Journal of Orthopaedic Trauma|October 21, 2024
Effects of Tranexamic Acid on Human Osteoblasts as Proxy for Fracture HealingAlexander Abraham, D Nicole Meyers, William D Rieger, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2013
E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironmentTao Yang, Ingo Grafe, Yangjin Bae, et al.
Antimicrobial Agents and Chemotherapy|March 21, 2018
Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrataJustin C Bader, Elizabeth A Lakota, Shawn Flanagan, et al.
Antimicrobial Agents and Chemotherapy|December 14, 2011
Pharmacodynamics of TD-1792, a novel glycopeptide-cephalosporin heterodimer antibiotic used against Gram-positive bacteria, in a neutropenic murine thigh modelSharath S Hegde, Olanrewaju O Okusanya, Robert Skinner, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2002
Fluid flow increases mineralized matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a dose-dependent mannerGregory N Bancroft, Vassilios I Sikavitsas, Juliette van den Dolder, et al.
Diagnostic Microbiology and Infectious Disease|April 26, 2011
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selectionOlanrewaju O Okusanya, Brian T Tsuji, Jurgen B Bülitta, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2011
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecyclineSujata M Bhavnani, Christopher M Rubino, Jeffrey P Hammel, et al.
Journal of Clinical Pharmacology|August 3, 2013
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumoniaScott A Van Wart, Alan Forrest, Tatiana Khariton, et al.
Diagnostic Microbiology and Infectious Disease|January 20, 2009
Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococciPaul G Ambrose, Alison K Meagher, Julie A Passarell, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase InhibitorPaul G Ambrose, Brian D VanScoy, Michael Trang, et al.
Pageof 25